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Evolution of multi-parametric MRI quantitative parameters
following transrectal ultrasound-guided biopsy of the prostate
A Latifoltojar1, N Dikaios1, A Ridout2, C Moore2, R Illing3, A Kirkham3, S Taylor1,3, S Halligan1,3, D Atkinson1, C Allen3, M Emberton2 and
S Punwani1,3
BACKGROUND: To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following
transrectal ultrasound (TRUS)-guided biopsy.
METHODS: Local ethical permission and informed written consent was obtained from all the participants (n= 14, aged 43–69, mean
64 years). Patients with a clinical suspicion of prostate cancer (PSA range 2.2–11.7, mean 6.2) and a negative (PIRAD 1–2/5) pre-
biopsy mp-MRI (pre-contrast T1, T2, diffusion-weighted and dynamic-contrast-enhanced MRI) who underwent 10-core TRUS-guided
biopsy were recruited for additional mp-MRI examinations performed at 1, 2 and 6 months post biopsy. We quantiﬁed mp-MRI
peripheral zone (PZ) and transition zone (TZ) normalized T2 signal intensity (nT2-SI); T1 relaxation time (T10); diffusion-weighted MRI,
apparent diffusion coefﬁcient (ADC); dynamic contrast-enhanced MRI, maximum enhancement (ME); slope of enhancement (SoE) and
area-under-the-contrast-enhancement-curve at 120 s (AUC120). Signiﬁcant changes in mp-MRI parameters were identiﬁed by analysis
of variance with Dunnett’s post testing.
RESULTS: Diffuse signal changes were observed post-biopsy throughout the PZ. No signiﬁcant signal change occurred following
biopsy within the TZ. Left and right PZ mean nT2-SI (left PZ: 5.73, 5.16, 4.90 and 5.12; right PZ: 5.80, 5.10, 4.84 and 5.05 at pre-biopsy,
1, 2 and 6 months post biopsy, respectively) and mean T10 (left PZ: 1.02, 0.67, 0.78, 0.85; right PZ: 1.29, 0.64, 0.78, 0.87 at pre-biopsy,
1, 2 and 6 months post biopsy, respectively) were reduced signiﬁcantly (Po0.05) from pre-biopsy values for up to 6 months post
biopsy. Signiﬁcant changes (Po0.05) of PZ-ME and AUC120 were observed at 1 month but resolved by 2 months post biopsy. PZ
ADC did not change signiﬁcantly following biopsy (P= 0.23–1.0). There was no signiﬁcant change of any TZ mp-MRI parameter at
any time point following biopsy (P= 0.1–1.0).
CONCLUSIONS: Signiﬁcant PZ (but not TZ) T2 signal changes persist up to 6 months post biopsy, whereas PZ and TZ ADC is not
signiﬁcantly altered as early as 1 month post biopsy. Caution must be exercised when interpreting T1- and T2-weighted imaging
early post biopsy, whereas ADC images are more likely to maintain clinical efﬁcacy.
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INTRODUCTION
Tumour localization using magnetic resonance imaging (MRI) is
increasingly important for the management of prostate cancer.
Pelvic imaging using T1- and T2-weighted MRI has conventionally
been used to locally stage prostate cancer following histological
conﬁrmation by transrectal ultrasound (TRUS)-guided biopsy.
However, biopsy itself can hamper localization of tumour on
anatomical MRI. For example, prostate cancer within the
peripheral zone (PZ) is typically of low T2-weighted signal
intensity compared with surrounding normal tissue. Consequently,
reduction of T2-weighted signal intensity from normal tissue
observed after biopsy1 can mask signiﬁcant cancer or cause
overestimation of disease extent.2
Previous work suggests that TRUS biopsy-induced anatomical
MRI signal changes can persist for up to 8 weeks3 and that
resolution is unpredictable.1,4 A strategy of delaying MRI following
biopsy has therefore evolved, with recommendations, based on
available evidence, postponing staging MRI until at least 3 weeks4
and up to 8 weeks after biopsy.3
More recently, MRI has emerged as a tool to detect prostate
cancer in patients with elevated risk. State-of-the-art multi-
parametric MRI (mp-MRI; T2-weighted, diffusion and dynamic
contrast-enhanced imaging) performed before biopsy enables
biopsy to be targeted, which may be more effective to diagnose
clinically signiﬁcant disease.5–7 Indeed, the recent update of
National Institute for Health and Care Excellence guidelines on
prostate cancer management recommend that mp-MRI is used for
patients with negative 10–12 cores TRUS biopsy (http://www.nice.
org.uk/guidance/cg175/chapter/recommendations). Understand-
ing the extent and duration of mp-MRI changes precipitated
by biopsy is central to minimizing their misinterpretation and
to identify the most appropriate delay between biopsy and
subsequent mp-MRI. However, work assessing the evolution of
imaging features following biopsy is limited and, where present,
such work has focused on qualitative assessment and compared
pre-biopsy mp-MRI with a single, but variable interval post-biopsy
mp-MRI. The natural history of mp-MRI signal change following
biopsy has not been addressed.1–4
This study systematically and quantitatively describes mp-MRI
signal evolution over a period of 6 months following TRUS-guided
biopsy.
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MATERIALS AND METHODS
Permission was obtained from the institutional ethics committee and
informed written consent was obtained from all the participants (REC
number: 08/H0714/21).
Patient recruitment
Fourteen patients (aged 43–69, mean 64 years) with (i) an elevated PSA
(range 2.2–11.7, mean 6.2) and (ii) a negative pre-biopsy prostate mp-MRI
report (PI-RADS score of equal or less than 2/5)8 were recruited
prospectively. Prostate volume calculated from pre-biopsy T2-weighted
images ranged from 17 to 80 cm3 (mean 52.7 cm3). All the patients
underwent a standard ultrasound-guided 10-core TRUS biopsy procedure.9
The patients then returned for additional mp-MRI scans performed at 1, 2
and 6 months post biopsy.
Multi-parametric MRI protocol
Participants were imaged using a 1.5 T MRI scanner (Avanto; Siemens,
Erlangen, Germany). With the patient supine, the manufacturers body coil
was used for signal excitation and a six-element surface phased-array coil
used for reception. To reduce peristalsis, 20 mg of butylscopolamine
bromide (Buscopan; Boehringer-Ingelheim, Ingelheim, Germany) was
administered intravenously before image acquisition.
Three-millimetre-thick axial and coronal small ﬁeld of view T2-weighted
images were acquired using a turbo spin echo sequence. Five-millimetre-
thick diffusion-weighted imaging was performed using short tau
inversion recovery echo planar imaging at b0, 150, 500 and 1000 s mm−2
(each averaged 16 times). Apparent diffusion coefﬁcient (ADC) maps
were generated using all the acquired b-values. For T1 quantiﬁcation, axial
pre-contrast T1-weighted images at multiple ﬂip angles were acquired
using a volume-interpolated gradient echo sequence. Dynamic contrast-
enhanced (DCE) imaging was performed during free breathing
using repeated volume-interpolated gradient echo acquisitions at a
ﬁxed ﬂip angle with a temporal resolution of 17 s and a total of 35
measures. A total 0.1 mmol kg− 1 gadoterate meglumine (Dotarem,
Guerbet, Villepinte, France) followed by a 10ml saline ﬂush was injected
intravenously at 3 ml s− 1 at the start of the sixth measure. Full sequence
parameters are provided in Table 1.
Image analysis
Image analysis was performed using Jim software (Jim, Xinapse Systems,
Version 6, Leicester, UK) by two observers in consensus, with 10 and 3
years experience of interpretation of prostate MRI, respectively. Pre-
contrast multiple ﬂip angle T1-weighted, axial T2-weighted, ADC maps and
DCE images were evaluated for each patient at each time point.
To provide patient level data, the prostate was manually segmented by
individually contouring the left and right PZ and left and right transition
zone (TZ) on each axial slice depicting the prostate at each time point.
To assess cohort level changes, the mean value from whole left and right
peripheral zone, and whole left and right TZ (that is, across all the slices of
a patient) on pre-contrast T1-weighted, T2-weighted and ADC images was
derived for each patient at each time point.
Furthermore, a single region of interest was placed centrally within the
right obturator internus muscle on T2-weighted images of each patient to
Table 1. MRI sequence parameters
T2 TSE T1 GRE (T10 quantiﬁcation) EPI-DWI T1 GRE (DCE quantiﬁcation)
TE/TR (ms) 92/5170 2.5/5.61 96/2100 2.5/5.61
Slice thickness (mm) 3 3 5 3
Spacing between slices (mm) 3.3 NA 5 NA
Number of averages 2 1 16 1
Matrix 256× 256 192× 192 172× 172 192× 192
Echo train length 17 1 1 1
Flip angle (degree) 180 5, 10, 20, 25 90 15
Field of view (mm) 180 258 340 258
Abbreviations: DCE, dynamic contrast enhancement; DWI, diffusion-weighted imaging; EPI, echo planar imaging; GRE, gradient echo; MRI, magnetic resonance
imaging; NA, not available; TE, echo time; TR, repetition time; TSE, turbo spin echo.
Table 2. Cohort-based change of quantitative MRI parameters
Side Scan Mean nT2-SI (s.d.) Mean T10 (s.d.) Mean ADC (s.d.) Mean ME (s.d.) Mean SoE (s.d.) Mean AUC120 (s.d.)
Peripheral zone Left Pre-biopsy 5.73 (1.15) 1.02 (0.19) 1.29 (0.13) 0.93 (0.27) 1.28 (0.49) 1.93 (0.53)
1-month 5.16 (1.03)a 0.67 (0.26)a 1.30 (0.13) 0.72 (0.32) 0.91 (0.41) 1.51 (0.63)
2-month 4.90 (1.00)a 0.78 (0.18)a 1.27 (0.11) 0.98 (0.21) 1.14 (0.55) 1.99 (0.42)
6-month 5.12 (1.35)a 0.85 (0.15)a 1.28 (0.11) 1.00 (0.24) 1.28 (0.75) 2.08 (0.50)
Right Pre-biopsy 5.8 (1.09) 1.04 (0.22) 1.29 (0.14) 1.01 (0.31) 0.96 (0.46) 1.57 (0.59)
1-month 5.10 (1.18)a 0.64 (0.26)a 1.29 (0.14) 0.76 (0.33)a 1.37 (0.66) 2.07 (0.90)
2-month 4.84 (1.17)a 0.78 (0.09)a 1.25 (0.18) 0.93 (0.18) 1.09 (0.62) 1.87 (0.44)
6-month 5.05 (1.14)a 0.87 (0.15) 1.29 (0.13) 0.99 (0.27) 1.26 (0.44) 1.86 (0.57)
Transition zone Left Pre-biopsy 3.61 (0.57) 0.85 (0.14) 0.89 (0.14) 1.41 (0.32) 1.16 (0.68) 2.12 (0.57)
1-month 3.39 (0.73) 0.84 (0.15) 0.92 (0.14) 1.33 (0.31) 1.58 (1.08) 3.39 (1.31)a
2-month 3.19 (0.63) 0.82 (0.08) 0.91 (0.14) 1.47 (0.23) 1.62 (1.41) 3.09 (1.32)
6-month 3.31 (0.73) 0.83 (0.08) 0.94 (0.15) 1.44 (0.20) 1.71 (0.82) 2.68 (0.55)
Right Pre-biopsy 3.44 (0.58) 0.87 (0.11) 0.87 (0.15) 1.37 (0.33) 1.32 (0.65) 2.50 (0.83)
1-month 3.34 (0.64) 0.88 (0.09) 0.9 (0.17) 1.37 (0.20) 1.29 (0.65) 2.52 (0.52)
2-month 3.24 (0.61) 0.87 (0.08) 0.88 (0.17) 1.47 (0.17) 1.85 (0.86) 2.78 (0.44)
6-month 3.30 (0.56) 0.84 (0.08) 0.91 (0.15) 1.45 (0.24) 1.34 (0.88) 2.68 (0.58)
Abbreviations: ADC, apparent diffusion coefﬁcient; AUC120, area under contrast-enhancement time curve up to 120 s; ME, maximum enhancement of contrast-
enhancement time curve; MRI, magnetic resonance imaging; nT2-SI, normalized T2-weighted signal intensity; SoE, slope of enhancement of contrast-
enhancement time curve; T10, T1 relaxation time.
aSigniﬁcant change (Po0.05) compared with pre-biopsy value.
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act as a reference for normalization of T2-weighted signal. Normalized T2-
weighted signal intensities (nT2-SI) were calculated by deriving a ratio of
prostate zone: obturator internus signal.
Curve ﬁtting of signal intensity measurements at multiple ﬂip angles
was used to derive T1 relaxation time (T10). For dynamic contrast-
enhanced images, a single signal intensity time curve was derived from
the mean of all voxels within each zone. Initial slope of enhancement (SoE)
and maximum enhancement (ME) was extracted as previously reported.10
In addition, the area under the contrast-enhancement time curve
from arrival of contrast within the prostate to 120 s (AUC120) was
determined.
Statistical analysis
A repeated measures analysis of variance followed by Dunnett’s multiple
comparison post testing; and a ordinary one-way analysis of variance
followed by Dunnett’s multiple comparison post testing was used to
identify signiﬁcant differences between mean mp-MRI parameters for each
post-biopsy time point compared with pre-biopsy baseline values on a
cohort level and per-patient level, respectively.
RESULTS
All the patients attended each of the four mp-MRI scanning
sessions. All pre-biopsy mp-MRI studies were prospectively
reported negative for signiﬁcant cancer (PI-RADS 1–2/5). In
addition, even with biopsy results available, in retrospect, no
tumour was localized on pre-biopsy MRI studies. There was no
signiﬁcant biopsy complication. Five patients were diagnosed with
1 core of 1mm Gleason 3+3 tumour and one patient had 1 core of
3mm of Gleason 3+4. All cores from the remaining patients
were benign. No treatment was administered to biopsy-positive
patients during the follow-up period. Mean values for all
quantitative parameters pre- and post-biopsy time points are
given in Table 2.
In all the patients, diffuse signal changes were evident
throughout the PZ following biopsy, whereas no perceptible
change was evident within the TZ.
Figure 1. Representative axial T2-weighted images at the mid-gland demonstrate (a) normal peripheral zone T2 signal intensity
pre-biopsy; and reduction (white arrows) in the peripheral zone T2 signal intensity at (b) 1 month, (c) 2 months and (d) 6 months post
biopsy.
Figure 2. Temporal change of mean (error bars± s.d.) normalized T2
signal intensity (nT2 SI) in the (a) left peripheral zone (PZ; red line),
(b) right peripheral zone (green line), (c) left transition zone (TZ;
orange line) and (d) right transition zone (black line). Signiﬁcant
changes are indicated in Table 2.
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Normalized T2-weighted signal intensity
A typical example of T2 signal evolution is shown in Figure 1. Two
patients were excluded from the analysis of nT2-SI change
because baseline T2-weighted MRI imaging parameters violated
the required trial protocol deﬁned in Table 1. Temporal change of
mean pre-biopsy nT2-SI (n= 12) for left and right peripheral and
transition zone is illustrated in Figure 2. For both left and right
peripheral zones, nT2-SI was reduced signiﬁcantly compared with
pre-biopsy values at 1, 2 and 6 months (left PZ mean nT2-SI; 5.73,
5.16, 4.90 and 5.12 at pre-biopsy, 1, 2 and 6 months post-biopsy,
respectively, Po0.05; right PZ mean nT2-SI; 5.80, 5.10, 4.84 and
5.05 at pre-biopsy, 1, 2 and 6 months post-biopsy, respectively,
Po0.05). There was no signiﬁcant difference between transition
zone nT2-SI between baseline and any post-biopsy time point
(P= 0.10 to 0.82; Table 2). Patient level PZ and TZ nT2-SI change
following TRUS biopsy are presented in Table 3 (a) and (b),
Table 3. Post-biopsy patient level nT2-SI, ADC and T10 signal change
 (a) Peripheral zone 
Mean nT2-SI  Mean ADC  Mean T10
Baseline vs. 
1 month 
post-biopsy 
Baseline vs. 
2 month 
post-biopsy 
Baseline vs. 
6 month 
post-biopsy 
 Baseline vs. 
1 month 
post-biopsy 
Baseline vs. 
2 month 
post-biopsy 
Baseline vs. 
6 month 
post-biopsy 
 Baseline vs. 
1 month 
post-biopsy 
Baseline vs. 
2 month 
post-biopsy 
Baseline vs. 
6 month 
post-biopsy 
1
2
3
4
5
6
7
8
9
10 
11 
12 
13 
14 
(b) Transition zone 
Mean nT2-SI  Mean ADC  Mean T10
Baseline vs. 
1 month 
post-biopsy 
Baseline vs. 
2 month 
post-biopsy 
Baseline vs. 
6 month 
post-biopsy 
 Baseline vs. 
1 month 
post-biopsy 
Baseline vs. 
2 month 
post-biopsy 
Baseline vs. 
6 month 
post-biopsy 
 Baseline vs. 
1 month 
post-biopsy 
Baseline vs. 
2 month 
post-biopsy 
Baseline vs. 
6 month 
post-biopsy 
1
2
3
4
5
6
7
8
9
10 
11 
12 
13 
14 
Abbreviations: ADC, apparent diffusion coefﬁcient; nT2-SI, normalized T2-weighted signal intensity; T10, T1 relaxation time. Signiﬁcant change, compared with
baseline, following ordinary one-way analysis of variance and Dunnett’s multiple comparison test, is illustrated by grey boxes. White boxes represent
nonsigniﬁcant signal change. Black boxes represent non-evaluable data.
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respectively. Signiﬁcant change from baseline of nT2-SI was
evident in the PZ in 12/12 patients, and in the TZ in 9/12 patients
at one or more post-biopsy time points.
Diffusion-weighted imaging—apparent diffusion coefﬁcient
An example of temporal ADC and source b-value diffusion-
weighted images changes are illustrated in Figures 3 and 4,
respectively. Mean pre-biopsy ADC (n= 14) for left and right
peripheral and transition zone is shown in Table 2 and Figure 5.
There was no signiﬁcant difference in baseline ADC for any zone
when compared with post-biopsy time points (P= 0.23 to 1.0).
Patient level PZ and TZ ADC change following TRUS biopsy are
presented in Table 3 (a) and (b), respectively. Signiﬁcant change
from baseline of ADC was evident in the PZ in 7/14 patients, and
in the TZ in 7/14 patients at one or more post-biopsy time points.
Pre-contrast T1-weighted MRI
Evolution of T1 signal is illustrated in Figure 6. Mean pre-biopsy
T10 (n= 14) for left and right peripheral and transition zone is
depicted in Table 2. T10 was signiﬁcantly lower at 1 month,
2 months and 6 months for the left peripheral zone (mean T10;
1.02, 0.67, 0.78, 0.85 at pre-biopsy, 1, 2 and 6 months post biopsy,
respectively, Po0.05; Figure 7) and at 1 month and 2 months for
the right peripheral zone (mean T10; 1.29, 0.64, 0.78, 0.87 at pre-
biopsy, 1, 2 and 6 months post biopsy, respectively, Po0.05;
Figure 7). There was no signiﬁcant difference between pre-biopsy
T10 and 1 month, 2 months and 6 months T10 within left and right
transition zones (P= 0.76 to 1.0; Figure 7). Patient level PZ and TZ
T10 change following TRUS biopsy are presented in Table 3 (a) and
(b), respectively. Signiﬁcant change from the baseline of T10 was
evident in the PZ in 12/14 patients and in the TZ in 4/14 patients
at one or more post-biopsy time points.
Dynamic contrast-enhanced imaging
There was no consistency between changes on both sides of the
gland for DCE MRI parameters. Mean ME (n= 14) at 1 month post
biopsy was signiﬁcantly lower within the right peripheral zone
(right PZ mean ME; 1.01 and 0.76 at pre-biopsy and 1 month post
biopsy, respectively, Po0.05); and mean AUC120 (n= 14) was
signiﬁcantly higher at 1 month post biopsy (Po0.05) within the
left transition zone compared with pre-biopsy values (left TZ mean
AUC120; 2.12 and 3.39 at pre-biopsy and 1 month post biopsy,
respectively). There was no other signiﬁcant difference for ME, SoE
and AUC120 between pre-biopsy and post-biopsy time points
(P= 0.06 to 1.0).
DISCUSSION
Our study documents the natural history of biopsy-induced mp-
MRI signal changes and their effect on derived quantitative mp-
MRI parameters. We observed signiﬁcant changes in nT2-SI and
T10 following biopsy persisting up to 6 months following biopsy.
We found no signiﬁcant change for ADC when pre-biopsy values
were compared with any post-biopsy time point. For dynamic
contrast-enhanced MRI-derived parameters, we found signiﬁcant
but inconsistent changes.
Our work conﬁrms that, as observed in the works of others,
peripheral zone T2-weighted signal intensity is reduced signiﬁ-
cantly 1 month following TRUS biopsy.11 Moreover, we found that
a small (mean 12%) but signiﬁcant reduction in T2 signal persists
Figure 3. Representative axial apparent diffusion coefﬁcient (ADC) maps at the mid-gland level from a patient within the cohort demonstrate
(a) normal peripheral zone ADC pre-biopsy; and stable ADC at (b) 1 month, (c) 2 months and (d) 6 months post biopsy.
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even at 6 months afterwards. Furthermore, we conﬁrmed that
nT2-SI within the transition zone does not change signiﬁcantly
following TRUS biopsy. One possible explanation is that the
absence of signiﬁcant change within the transition zone likely
reﬂects undersampling of the anterior gland by the biopsy
procedure.12 Previous work illustrates that the T2 signal of PZ
tumour is on average reduced by 25% compared with normal PZ
and TZ.13 We demonstrated maximum average change of 15–17%
in T2 signal of normal PZ at 2 months post biopsy and 11–13% at
6 months post biopsy. It is possible that persistent changes of T2
signal intensity even after 6 months could potentially hinder MRI
diagnostic performance, especially for low-grade and/or diffuse
tumour.
Although studies have described changes in T1 signal intensity
within the prostate following biopsy,14 quantitative changes in T1
relaxation time have not been described previously. We found
that T10 decreased signiﬁcantly after biopsy, consistent with the
increase in T1 signal intensity reported previously and ascribed to
post-biopsy haemorrhage.14,15 In keeping with the evolution of
T2 signal changes, T1 signal changes also start to normalize by
6 months post biopsy and remain signiﬁcantly different compared
with pre-biopsy values.
We observed that ADC was not signiﬁcantly different from pre-
biopsy values at 1, 2 and 6 months post biopsy. Rosenkrantz
et al.16 previously compared ADC of normal benign, haemorrhagic
peripheral zone and peripheral zone prostate cancer, and found
that ADC was reduced in the areas of haemorrhage. They did not
report the temporal evolution of ADC change, and patients
recruited were imaged at a wide range of intervals following
biopsy but grouped for analysis (range 10 to 241 days, mean
63 days). In contrast, our biopsy cohort mp-MRI scans were
acquired at pre-speciﬁed time points and did not demonstrate any
signiﬁcant change following biopsy at our earliest interval of
1 month. However, we acknowledge that ADC changes have been
associated with haemorrhage in neuroimaging, with hyperacute,
acute and early subacute stages causing reduced ADC, which then
Figure 4. Representative axial multiple b-value diffusion-weighted images at the mid-gland level for the apparent diffusion coefﬁcient
maps illustrated in Figure 3. Columns (left to right) represent baseline, 1-, 2-, 6-month post-biopsy time points. Rows (top to bottom)
represent b0, b150, b500 and b1000 images. No visual change is evident from baseline for any diffusion weighting at 1, 2 and 6 months post
biopsy.
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normalize at subacute and chronic stages.17 It is possible that
Rosenkrantz et al.16 included post-biopsy patients with acute
haemorrhage, while our earliest post-biopsy imaging mp-MRI
corresponds to the subacute/chronic stage. Combined with our
study, results suggest that ADC change does occur but normalizes
in 1 month.
It is difﬁcult to draw ﬁrm conclusions from our DCE results. We
hypothesized that TRUS biopsy should affect both sides of the
Figure 5. Temporal changes of mean apparent diffusion coefﬁcient
(ADC; error bars± s.d.) in the (a) left peripheral zone (PZ; red line), (b)
right peripheral zone (green line), (c) left transition zone (TZ; orange
line) and (d) right transition zone (black line). No signiﬁcant changes
were observed in any zone (Table 2).
Figure 6. Representative axial T1-weighted images at the mid-gland level demonstrate (a) normal peripheral zone T1 signal intensity pre-
biopsy; and increase (white arrows) in the peripheral zone T1 signal intensity at (b) 1 month, (c) 2 months and (d) 6 months post biopsy.
Figure 7. Temporal changes of mean T1 relaxation rate (T10; error
bars± s.d.) in the (a) left peripheral zone (PZ; red line), (b) right
peripheral zone (green line), (c) left transition zone (TZ; orange line)
and (d) right transition zone (black line). Signiﬁcant changes are
indicated in Table 2.
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gland equally and any resulting spatial differences would average
out across patients. We believe that inconsistent signiﬁcant
ﬁndings between left and right zones, despite the presence of
diffuse PZ signal increase on pre-contrast T1-weighted images,
reﬂect poor repeatability/reproducibility (also evidenced by the
relatively large standard deviation of these measurements) of
DCE-derived quantitative measures.18
We observed diffuse signal changes in all the patients following
biopsy. We believe that the volumetric sampling accurately
reﬂects quantitative mp-MRI parameter changes within our
population. Moreover, previous work has shown that volumetric
analysis of quantitative derived parameters is more repeatable
than single-slice region of interest-based quantiﬁcation.19
Our results suggest that if mp-MRI is performed at least 1 month
following biopsy, then ADC is least affected and, therefore,
will likely be the most reliable method for localizing disease.
Also, based on the ﬁnding that anterior gland nT2-SI, T10 and ADC
are not affected signiﬁcantly even at 1 month, reliable imaging of
the anterior gland with mp-MRI following TRUS biopsy is possible
and could be performed early in patients with a negative TRUS
biopsy and high PSA for rapid assessment of anterior gland
cancers that may be undersampled by TRUS biopsy. We believe
that ADC maps at 1 month may help imaging assessment of non-
targeted biopsy-positive low-risk prostate cancer to exclude
undersampled disease, and to evaluate the suitability of
intermediate risk biopsy-positive cancer for potential focal
therapy.
Finally, the observation that nT2-SI and T10 changes persist at
6 months re-highlights that caution should be applied when
relying on anatomical imaging alone for detection and staging
prostatic cancer.
There are several limitations to our study. First, our choice
of imaging time points was pragmatic, based on clinically
useful intervals and patient convenience. Accordingly, we did
not assess the immediate effects of biopsy nor whether the
signal changes induced by biopsy persisted for longer than
6 months. Second, quantitative DCE MRI parameters revealed
inconsistent changes with relatively large standard deviations;
whether these ﬁndings relate to relatively low temporal resolution
of our DCE data set remains unclear. Third, we did not assess the
impact of post-biopsy changes on quantitative derived para-
meters from mp-MRI scans that were positive for tumour.
No visible tumour was evident on mp-MRI for patients
included within this study. There is a growing consensus that
such disease can be monitored with active surveillance.20
However, disease that is visible on mp-MRI is more likely to be
of higher risk21 and, as such, warrants intervention. Hence,
we were unable to recruit patients with mp-MRI visible disease,
as a 6-month delay to treatment with high-risk prostate cancer
was deemed unethical.
We expect, from the work of others, that reduced levels of
citrate in areas of prostate cancer will result in reduced post-
biopsy haemorrhage within the tumour region compared with
normal surrounding prostate tissue.1,22 Indeed, ADC within
tumour may be even less susceptible to biopsy effect than
indicated by our results.
We have grouped low-risk MRI-non-visible tumour (n= 6)
patients along with those without cancer (n= 8), given that the
radiological phenotype of both is the same, that is, a negative mp-
MRI study. This is in keeping with the growing consensus on non-
treatment of ‘insigniﬁcant’ prostate cancer.23,24
In summary, signiﬁcant PZ (but not TZ) T2 signal changes persist
up to 6 months post biopsy, whereas PZ and TZ ADC is not
signiﬁcantly altered as early as 1 month post biopsy. Caution must
be exercised when interpreting T1- and T2-weighted imaging
early post biopsy, whereas ADC images are more likely to maintain
clinical efﬁcacy.
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